However, activation of NFκB in human myeloma cell lines (HMCLs) and primary MM cells has been explained partly by detection of some mutations in NFκB-controlled/related genes (mostly in alternative pathway) [19], [20], and are probably independent of TLR signaling which is normally through the canonical pathway [21], [22]. This evidence concerns the gene NFKB1 and Miyoshi myopathy.